Lixte Biotechnology Holdings, Inc.
LIXT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.03 | 0.06 | -0.03 |
| FCF Yield | -69.31% | -95.55% | -57.16% | -25.84% |
| EV / EBITDA | -0.99 | 90.37 | -2,575.86 | -1,409.90 |
| Quality | ||||
| ROIC | -431.93% | -127.42% | -118.66% | -136.16% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.88 | 0.84 | 0.73 | 0.62 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 26.29% | 6.91% | -11.32% | -94.37% |
| Safety | ||||
| Net Debt / EBITDA | 0.29 | -1,311.13 | 5,079.12 | 606.68 |
| Interest Coverage | 0.00 | 0.00 | -711.15 | -906.45 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |